Onesource Specialty Pharma Ltd. Share Price

ONESOURCE INDUSTRIES: AGRITECH EXPANSION & RIGHTS ISSUE

approved a capital raise of up to ₹52.45 Crores via a Rights Issue, executed an agritech marketplace development contract with LCC Infotech, and approved a new US-based subsidiary (Onesource Industries & Ventures LLC). This pivot into digital agricultural infrastructure broadens the company's operational scope. However, key commercial terms—including total contract value and rights issue pricing—were omitted, making immediate earnings quantification unfeasible. The execution timeframe spans approximately 24 months, indicating that meaningful commercial revenues and cash flows will materialise only in later phases. Key risks include software execution delays, platform user adoption, and potential equity dilution from the sizeable rights issue. Given the 24-month development cycle and incomplete commercial details, a HOLD stance is warranted until rights issue terms and platform deployment milestones are clarified.

OneSource Speciality Pharma Limited Results Analysis-Q1FY27

Firstsource Solutions Limited

Supports Second Generic Semaglutide Approval in Canada - OneSource Specialty Pharma Ltd

Code BSE: 544292 NSE:

STOCKS TO KEEP ON RADAR – WEEKLY TOP GAINERS

Elecon Engineering (ELECON) - Elecon Engineering has witnessed a massive breakout this week, gaining 24.2% to close at ₹1,135.55 on April 24, 2026. The stock is currently in a "super-bullish" phase, characterized by high volume and price action well above historical averages. The stock is trading significantly above all major EMA levels, which indicates strong upward momentum and a healthy long-term trend. RSI (14-day) is currently at 78.42, placing the stock in the overbought zone. But, the MACD histogram shows expanding green bars, indicating that the bullish momentum is accelerating. OneSource Specialty Pharma (ONESOURCE) - OneSource Specialty has showed impressive strength this week, surging 18.2% to close at ₹488.50 on April 24, 2026. The stock has successfully broken out of a multi-week consolidation phase on the back of heavy buying volume. The stock’s price action is firmly bullish, as it is currently trading well above its short-term and medium-term moving averages. RSI (14-day) is currently at 72.15. This indicates the stock is entering the overbought zone. But, the MACD line has staged a bullish crossover above the signal line. The histogram is turning positive and expanding, suggesting that the upward trend is gaining strength.